BateCMBoothSNCroweJPDoes 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis?Aliment Pharmacol Ther1993;7:501–7.
2.
FassRSontagSJTraxlerBTreatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol2006;4:50–6.
3.
CheyWDEswarenSHowdenCWPrimary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Aliment Pharmacol Ther2006;23:655–68.
4.
CharbelSKhandwalaFVaeziMF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol2005;100:283–9.
5.
TamhankarAPPetersJHPortaleGOmeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg2004;8:890–8.
6.
KoekGHSifrimDLerutTEffect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut2003;52:1397–1402.
7.
MainieITutuianRAgrawalACombined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg2006;93:1483–7.
